Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

3(75.0%)

Phase 3

1(25.0%)

4Total

Phase 4(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00123604Phase 4Completed

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Role: lead

NCT00459056Phase 3Completed

The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients

Role: lead

NCT00546728Phase 4Completed

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

Role: lead

NCT00123643Phase 4Completed

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

Role: lead

NCT01169441Completed

Lead Extract Study

Role: lead

All 5 trials loaded